A Phase II Study of E7 TCR T Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
Latest Information Update: 03 Feb 2022
At a glance
- Drugs KITE 439 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Dec 2021 Status changed from suspended to discontinued.
- 16 Apr 2021 Status changed from recruiting to suspended at the discretion of the PI.
- 04 Jul 2020 Planned initiation date (estimated date for recruitment of the first subject) changed to 10 Jul 2020.